Have a personal or library account? Click to login
Baseline tumor Lipiodol uptake after transarterial chemoembolization for hepatocellular carcinoma: identification of a threshold value predicting tumor recurrence Cover

Baseline tumor Lipiodol uptake after transarterial chemoembolization for hepatocellular carcinoma: identification of a threshold value predicting tumor recurrence

Radiology and Oncology
Volume 51 (2017): Issue 4 (December 2017)
By: Yusuke Matsui,  Masahiro Horikawa,  Younes Jahangiri Noudeh,  John A. Kaufman,  Kenneth J. Kolbeck and  Khashayar Farsad  
Open Access
|Jul 2017

Figures & Tables

Figure 1

Baseline Lipiodol uptake after TACE for HCC. Significantly higher Lipiodol uptake was noted in tumors without recurrence and in tumors treated selectively with TACE.
Baseline Lipiodol uptake after TACE for HCC. Significantly higher Lipiodol uptake was noted in tumors without recurrence and in tumors treated selectively with TACE.

Figure 2

Baseline Lipiodol uptake and washout rate in relation to early tumor recurrence. Early recurring tumors demonstrated significantly lower baseline Lipiodol uptake and higher Lipiodol washout rates relative to tumors recurring after the median recurrence free interval (= 3 months) and tumors with no recurrence.
Baseline Lipiodol uptake and washout rate in relation to early tumor recurrence. Early recurring tumors demonstrated significantly lower baseline Lipiodol uptake and higher Lipiodol washout rates relative to tumors recurring after the median recurrence free interval (= 3 months) and tumors with no recurrence.

Figure 3

ROC curve showing the area under curve and optimal cutoff value of baseline Lipiodol uptake after TACE to predict tumor recurrence.
ROC curve showing the area under curve and optimal cutoff value of baseline Lipiodol uptake after TACE to predict tumor recurrence.

Figure 4

Comparison of the cumulative hazards of tumor recurrence over the follow-up period between baseline Lipiodol uptake above and below the identified threshold. Tumors with Lipiodol uptake < 270.2 HU demonstrated significantly higher hazards of recurrence after TACE.
Comparison of the cumulative hazards of tumor recurrence over the follow-up period between baseline Lipiodol uptake above and below the identified threshold. Tumors with Lipiodol uptake < 270.2 HU demonstrated significantly higher hazards of recurrence after TACE.

Figure 5

ROC curve showing the area under curve and optimal cutoff value of Lipiodol washout rate after TACE to predict early tumor recurrence.
ROC curve showing the area under curve and optimal cutoff value of Lipiodol washout rate after TACE to predict early tumor recurrence.

Figure 6

Comparison of the cumulative hazards of tumor recurrence over the follow-up period between Lipiodol washout rates above and below the identified threshold. Tumors with Lipiodol washout rates ≥ 37.8 HU/month demonstrated significantly higher hazards of recurrence after TACE.
Comparison of the cumulative hazards of tumor recurrence over the follow-up period between Lipiodol washout rates above and below the identified threshold. Tumors with Lipiodol washout rates ≥ 37.8 HU/month demonstrated significantly higher hazards of recurrence after TACE.

Summary of the study population

Characteristics
Patients
Age (years)59.9 ± 7.9
GenderFemale 12 (40.0%)
Male 18 (60.0%)
HCV 13 (43.3%)
HCV + Alcohol 7 (23.3%)
Liver disease etiologyAlcohol 4 (13.3%)
HBV 1 (3.3%)
Other 5 (16.7%)
Child-Pugh classA 10 (33.3%)
B 20 (66.7%)
BCLC stageA 17 (56.7%)
B 13 (43.3%)
Tumors
Baseline tumor size (mm) 20.3 ± 10.1
Lobar 16 (34.8%)
Treatment selectivitySegmental 22 (47.8%)
Sub-segmental 8 (17.4%)
Baseline Lipiodol uptake (HU) 328.3 ± 185.2
Lipiodol uptake at final evaluation (HU) 205.0 ± 219.5
Washout (HU) 136.9 ± 127.6
Follow-up time (months) 5.6 ± 6.2
Tumor recurrenceYes 19 (41.3%)
No 27 (58.7%)

Results of cox regression analysis to predict factors for tumor recurrence

Predicting factorUnivariate modelMultivariate model

Variables with a p value less than 0.200 were entered in the multivariate model.

Hazard ratio (CI)p ValueHazard ratio (CI)p Value
Lesion size (mm)0.70 (0.24-2.09)0.527--
Treatment selectivity (Segmental or subsegmental vs. lobar)0.19 (0.07–0.51)0.0013.05 (0.62–15.05)0.171
Baseline Lipiodol uptake (HU)0.37 (0.19–0.70)0.0020.002 (0.0–0.087)0.001
Presence of Lipiodol washoutNA

Not calculated because no tumors without Lipiodol washout recurred while 65.5% (19/29) of the tumors with Lipiodol washout recurred.

NA--
Washout rate (HU/month)3.37 (1.78–6.36)< 0.0001149.03 (11.20–1983.54)< 0.0001
DOI: https://doi.org/10.1515/raon-2017-0030 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 393 - 400
Submitted on: Apr 16, 2017
|
Accepted on: Jun 30, 2017
|
Published on: Jul 18, 2017
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
transarterial chemoembolization,
hepatocellular carcinoma,
Lipiodol,
tumor response,
threshold
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2017 Yusuke Matsui, Masahiro Horikawa, Younes Jahangiri Noudeh, John A. Kaufman, Kenneth J. Kolbeck, Khashayar Farsad, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 51 (2017): Issue 4 (December 2017)Next article